<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2900.2769" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<DIV><FONT face=Tahoma size=2>
<DIV>Estimadas y estimados </DIV>
<DIV>esta disponible el <FONT size=2>WHO Pharmaceuticals New<FONT
face="Times New Roman">s</FONT><FONT face="Times New Roman">l</FONT><FONT
face="Times New Roman">etter</FONT><FONT face="Times New Roman">
No.</FONT></FONT> <FONT face="Times New Roman" size=2>4, 2005</FONT></DIV>
<DIV>contenido</DIV>
<DIV>Regulatory Matters<BR></DIV>
<DIV>Amfetamine -- Reintroduced with revised prescribing and patient information
............................... 1<BR>Atomoxetine -- Risk of suicidal
thoughts.........................................................................
1<BR>Bacitracin, Fusafungine, Gramicidin, Tyrothricin -- Locally administered
products withdrawn ...... 2<BR>Cetuximab -- Recommendations for electrolyte
monitoring..................................................... 2<BR>Duloxetine
-- Reports of adverse hepatic effects
................................................................ 2<BR>Fentanyl
transdermal system -- Labels updated for safe and appropriate
use............................ 2<BR>Hexavac -- Suspended due to concerns about
long-term effects against hepatitis B..........................
3<BR>Medroxyprogesterone -- Loss of bone marrow density
....................................................... 3<BR>Meloxicam --
Juvenile rheumatoid arthritis indication: label updated
.......................................... 3<BR>Nabumetone -- Stronger labelling
for renal effects..............................................................
4<BR>Non-selective NSAIDs -- No changes to current prescribing
practice........................................ 4<BR>Paroxetine -- Potential
risk in pregnancy
..........................................................................
4<BR>Thioridazine -- Sale discontinued in Canada
.....................................................................
5<BR></DIV>
<DIV> </DIV>
<DIV>Safety of Medicines</DIV>
<DIV> </DIV>
<DIV><BR>Anti-TNF alpha products -- New measures to prevent activation of latent
tuberculosis ................... 6<BR>Beta-2 agonists -- Increased risks of
asthma-related deaths...................................................
6<BR>Cabergoline -- Use linked to
gambling............................................................................
6<BR>Codeine & hydrocodeine -- Akathisia with long-term
use.................................................... 6<BR>Ezetimibe --
Reports of muscle
pain...............................................................................
7<BR>Hydromorphone -- Co-ingestion with alcohol
harmful.......................................................... 7<BR>Ibuprofen
-- Reports of Stevens-Johnson
syndrome.............................................................
7<BR>Isotretinoin -- Strengthened risk management programme
.................................................... 8<BR>Trastuzumab --
Addition to chemotherapy increases toxicity
.................................................. 8<BR>Vinca alkaloids --
Intrathecal administration
reported...........................................................
8<BR>Feature<BR>Twenty-eighth Annual Meeting of Representatives of the National
Centres participating in the WHO<BR>Programme for International Drug Monitoring:
Observations from Working Group Exercises...........10</DIV>
<DIV> </DIV>
<DIV> </DIV>
<DIV>en la siguiente direccion</DIV>
<DIV><A
href="http://www.who.int/entity/medicines/publications/pn2005_4.pdf">http://www.who.int/entity/medicines/publications/pn2005_4.pdf</A></DIV>
<DIV> </DIV>
<DIV>Saludos,<BR>Martín</DIV>
<DIV> </DIV>
<DIV>Martin Cañás<BR>GAPURMED La Plata (Argentina)<BR><A
href="mailto:macanas@netverk.com.ar">macanas@netverk.com.ar</A></DIV></FONT></DIV></BODY></HTML>